[1]平军娇a,高永双b,邓顺顺a,等.广东省中山地区汉族精神类疾病患者药物基因型及代谢表型分布研究[J].现代检验医学杂志,2019,34(03):15-20，24.[doi:10.3969/j.issn.1671-7414.2019.03.004]
　PING Jun-jiaoa,GAO Yong-shuangb,DENGShun-shuna,et al.Research on Characteristics of Drug Genotypesand Metabolic Phenotypes in Chinese Han Patients with Severe MentalIllness in Zhongshan Area of Guangdong Province[J].Journal of Modern Laboratory Medicine,2019,34(03):15-20，24.[doi:10.3969/j.issn.1671-7414.2019.03.004]
点击复制

广东省中山地区汉族精神类疾病患者药物基因型及代谢表型分布研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年03期
页码:
15-20，24
栏目:
论著
出版日期:
2019-06-20

文章信息/Info

Title:
Research on Characteristics of Drug Genotypesand Metabolic Phenotypes in Chinese Han Patients with Severe MentalIllness in Zhongshan Area of Guangdong Province
文章编号:
1671-7414(2019)03-015-07
作者:
平军娇1a; 高永双1b; 邓顺顺1a; 章 杰1c; 万 静1c; 杜宝国1c; 钱 刚2
(1.中山市第三人民医院a.检验科; b.药剂科; c.早期干预科,广东中山 528451; 2.遵义医学院细胞生物学与遗传学教研室,贵州遵义 563099)
Author(s):
PING Jun-jiao1a; GAO Yong-shuang1b; DENGShun-shun1a; ZHANG Jie1c; WAN Jing1c; DU Bao-guo1c; QIAN Gang2
(1a.Department of Clinical Laboratory; 1b.Department of Pharmacy; 1c.Department of Early Intervention,Zhongshan Third People's Hospital,Guangdong Zhongshan 528451,China; 2.Departmentof Cell Biology and Genetics,Zunyi Medical University,Guizhou Zunyi 563099,China)
关键词:
药物基因组学;  精神分裂症;  心境障碍;  表型;  基因多态性
分类号:
R749.3; R394.6
DOI:
10.3969/j.issn.1671-7414.2019.03.004
文献标志码:
A
摘要:
目的 探讨中山地区汉族重性精神类疾病患者药物基因型及代谢基因表型特征,为重性精神疾病临床个体化选药提供代谢基因型临床参考。方法 随机选取2018年1月～2019年2月在中山市第三人民医院住院的患者155例,根据ICD-10疾病诊断标准将患者分为:精神分裂症组(A组,n=95)、心境障碍组(B组,n=30)和其他精神疾病组(C组,n=30)。采用飞行时间质谱检测技术,分析纳入患者的药物基因型和代谢表型,比较各基因型表型分布频率和特征。结果 155例样本中CYP2D6,CYP2C19和NAT2基因中间代谢型频率最多,分别为50.9%,52.9%和48.4%; CYP3A4基因全部为广泛代谢型(100%); CYP1A2基因发现两个表型,即超快代谢型(50.3%)和广泛代谢型(49.7%); CYP3A5,UGT2B15,UGT2B7和FKBP5基因型中突变纯合型频率最多,分别为51.6%,45.8%,53.6%和54.9%; 而MC4R和DRD2基因型中野生纯合型频率最高,分别为61.9%和51.0%。HTR2A和HTR2C基因型在所测样本中突变杂合型频率最多,分别为47.1%和99.4%。三组间基因代谢表型比较发现CYP2C19慢代谢型和NAT2基因慢代谢型差异有统计学意义(χ2=6.452～12.054,均P<0.05); 三组间基因型比较发现CYP3A5基因野生纯合型、UGT2B15基因突变杂合型、MC4R基因突变杂合型和野生纯合型差异均有统计学意义(χ2=5.907～12.40,均P<0.05)。结论 中间代谢型和突变纯合型分别是中山市重性精神疾病患者药物基因代谢表型及基因型的主要特征。
Abstract:
Objective To map the characteristics of drug genotypes and metabolic phenotypes in Chinese Han patients with severe mental illness in Zhongshan city.Methods 155 patients with severe mental illnesses were randomly involved and phenotypic analysis for drug genotypes and metabolic phenotypes based on exfoliated cells from patients'cheek weredetermined by time-of-flight mass spectrometry.The frequencies of individualgenotype were calculated and the genetic characteristics were compared in the diagnosis-specific groups,including schizophrenia group(A),mood disorder group(B)and other mental illnesses group(C).Results The frequencies of intermediate homozygous in CYP2D6,CYP2C19 and NAT2,were mostly found in 50.9%,52.9% and 48.4% respectively.Frequency of widely metabolic phenotype were found at CYP3A4 genes predominately(100%).There were two phenotypes in CYP1A2,namely,ultrafast metabolic type(50.3%)and extensive metabolictype(49.7%).Most of homozygousgenotypes were identified in CYP3A5,UGT2B15,UGT2B7 and FKBP5 with frequencies of 51.6%,45.8%,53.6% and 54.9% respectively.The frequencies of wild homozygotes in MC4R and DRD2 genotypes were 61.9% and 51.0% respectively.There were the most mutation heterozygosity frequenciesin HTR2A and HTR2C genotypes,which were 47.1% and 99.4% respectively.Metabolic phenotype comparison among the three groups showed significant differences inCYP2C19 slow metabolic type,NAT2 slow metabolic type(χ2=6.452～12.054,all P<0.05).Genotype comparison among the three groups showed significant differences in CYP3A5 wild homozygous type,UGT2B15 mutation heterozygous type,MC4R mutation heterozygous type and wild homozygous type(χ2=5.907～12.40,all P<0.05).Conclusion The intermediate homozygous and homozygous genotype are main characteristics for either drug genotypesor metabolic phenotypes for Chinese Han patients with severe mental illnesses at Zhongshan city.

参考文献/References:

[1] HAMILTON S P.The promise of psychiatric pharmacogenomics[J].Biol Psychiatry,2015,77(1):29-35.
[2] CRETTOL S,PETROVIC N,MURRAY M.Pharmacogenetics of phase I and phase IIdrug metabolism[J].Curr Pharm Des,2010,16(2):204-219.
[3] TING L S,BENOIT-BIANCAMANO M O,BER-NARD O,et al.Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients:an exploratory study[J].Pharmacotherapy,2010,30(11):1097-1108.
[4] MIKSYS S,TYNDALE RF.Cytochrome P450-mediated drug metabolism in the brain[J].J Psychiatry Neuro Sci,2013,38(3):152-163.
[5] 简斌,张涛,肖俊会,等.云南汉族人群CYP2C19基因多态性分析[J].昆明医科大学学报,2015,36(11):17-19. JIAN Bin,ZHANG Tao,XIAO Junhui,et al.Genetic polymorphism analysis of CYP2C19 in Yunnan Han population[J].Journal of Kunming Medical University,2015,36(11):17-19.
[6] 秦延海,古丽扎尔·买买提明,帕丽达·阿不来提.维吾尔族、哈萨克族、汉族人群CYP2C19基因多态性分析[J].重庆医学,2015,44(33):4632-4634. QIN Yanhai,GULIZHAER·Mainaitiming,PALIDA·Abulatib.Anlysis of genetic polymorphism of cytochrome CYP2C19 in Chinese Uighur,Kazak and Han populations[J].Chongqing Medicine,2015,44(33):4632-4634.
[7] 葛高顺,倪二茹,方宜臻,等.厦门地区心血管疾病患者外周血单个核细胞CYP2C19基因型与表型的分布研究[J].现代检验医学杂志,2018,33(4):8-11,15. GE Gaoshun,NI Erru,FANG Yizhen,et al.Study on the distribution of CYP2C19 genotypes and phenotypes mononuclear cells of peripheral blood from patients with cardiovascular diseases in Xiamen area[J].J Mod Lab Med,2018,33(4):8-11,15.
[8] 徐鹏,胡国艳,邱萍英,等.华南地区汉族精神分裂症患者CYP2C19基因多态性及代谢表型分析[J].深圳中西医结合杂志,2017,27(12):4-6. XU Peng,HU Guoyan,QIU Pingying,et al.Analysis of CYP2C19 gene polymorphism and metabolic phenotype in schizophrenic patients of Han nationalityin South China[J].Shenzhen Journal of Integrated Traditional Chinese and Western Medicine,2017,27(12):4-6.
[9] MAGGO S D,SAVAGE R L,KENNEDY M A.Impact of new genomic technologies onunderstanding adverse drug reactions[J].Clinical Pharmacokinetics,2016,55(4):419-436.
[10] 周健,李虓,王刚,等.中国健康人群与精神分裂症患者CYP2D6(C100T)遗传多态性的相关研究[J].现代检验医学杂志,2008,23(5):39-41.ZHOU Jian,LI Xiao,WANG Gang,et al.CYP2D6 genetic polymorphisms in Chinese healthy and schizophrenia populations[J].J Mod Lab Med,2008,23(5):39-41.
[11] 翟晓艳,崔炜,张亚楠,等.国人CYP2D6*10基因多态性研究[J].河北医科大学学报,2010,31(2):128-131.ZHAI Xiaoyan,CUI Wei,ZHANG Yanan,et al.Ge-ne polymorphisms ofCYP2D6*10 in Chinese population[J].J Hebei Med Univ,2010,31(2):128-131.
[12] 曾雷,元静,卫芋君,等.CYP2D6基因多态性与分裂症易感性及利培酮治疗反应的研究进展[J].国际精神病学杂志,2018,45(1):18-21.ZENG Lei,YUAN Jing,WEI Yujun,et al.The research progress on polymorphism of CYP2D6 gene and susceptibility to schizophrenia and risperidone treatment[J].Journal of International Psychiatry,2018,45(1):18-21.
[13] 刘芳,苗青,焦伟伟,等.NAT2和CYP2E1基因多态性及其代谢表型在中国汉族儿童中的分布[J].中国当代儿科杂志,2012,14(5):353-358.LIU Fang,MIAO Qing,JIAO Weiwei,et al.Genotype and phenotype polymorphisms of NAT2 and CYP2E1 in the Han Chinese pediatric population[J].Chin J Contemp Pediatr,2012,14(5):353-358.
[14] FLEEMAN N,MCLEOD C,BAGUST A,et al.The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics:a systematic review and economic evaluation[J].Health Technol Assess,2010,14(3):1-157,iii.
[15] MULLER D J,ZAI C C,SICARD M,et al.Systematic analysis of dopamine receptor genes(DRD1-DRD5)in antipsychotic induced weight gain[J].Pharmacogenomics J,2012,12(2):156-164.
[16] 陈柯霖,张国军,吕虹,等.CYP1A2基因C163A多态性与精神分裂症易感性的相关研究[J].中国医药生物技术,2015,10(2):182-183.CHEN Kelin,ZHANG Guojun,L(¨overU)Hong,et al.Co-rrelation study between polymophism of CYPIA2 gene C163A and susceptibility to schizophrenia[J].Chin Med Biotechnol,2015,10(2):182-183.
[17] SARGINSON J E,LAZZERONI L C,RYAN H S,et al.FKBP5 polymorphisms and antidepressant response in geriatric depression[J].American Journal of MedicalGenetics B:Neuropsychiatric Genetics,2010,153B(2):554-560.
[18] DI GIORGIO A,SMITH RM,FAZIO L,et al.DR-D2/CHRNA5 interaction on prefrontal biology and physiology during working memory[J].PLoS One,2014,9(5):e95997.
[19] Schizophrenia Working Group of the Psychiatric Genomics Consortum.Biological insights from 108 schizophrenia-associated genetic loci[J].Nature,2014,511(7510):421-427.
[20] 王丽萍,曾俊芬,宋金春.5-HTR2A 102T>C基因多态性与抗精神病药物疗效的Meta-分析[J].药物评价研究,2018,41(4):656-663.WANG Liping,ZENG Junfen,SONG Jinchun.Correlation of 5-HTR2A gene with102T>C polymorphism and clinical efficacy of antipsychotics based on meta-analysis[J].Drug Evaluation Research,2018,41(4):656-663.
[21] FAKRA E,AZORIN J M.Clozapine for the treatment of schizophrenia[J].Expert Opin Pharmacother,2012,13(13):1923-1935.

相似文献/References:

[1]苏显都a,范长玲a,于 莉a,等.琼西地区精神分裂症患者血浆MiR-137,MiR-181b及MiR-132表达及其相关性研究[J].现代检验医学杂志,2016,31(04):30.[doi:10.3969/j.issn.16717-414.2016.04.007]
　SU Xian-dua,FAN Chang-linga,YU Lia,et al.Expression of Plasma MiR-137,MiR-181b and MiR-132 of Schizophrenia Patients in Qiongxi Area and Its Correlation Study[J].Journal of Modern Laboratory Medicine,2016,31(03):30.[doi:10.3969/j.issn.16717-414.2016.04.007]
[2]苏显都a,范长玲a,于 莉a,等.血浆及单核细胞中microRNA表达水平与精神分裂症患者的相关性研究[J].现代检验医学杂志,2017,32(02):45.[doi:10.3969/j.issn.1671-7414.2017.02.012]
　SU Xian-dua,FAN Chang-linga,YU Lia,et al.Association of Epression with the Level of MicroRNA in Plasma and Mononuclear Cells in Patients with Schizophrenia[J].Journal of Modern Laboratory Medicine,2017,32(03):45.[doi:10.3969/j.issn.1671-7414.2017.02.012]
[3]谭梅娟,李 靖.精神分裂症患者梅毒感染的流行病学调查[J].现代检验医学杂志,2018,33(04):125.[doi:10.3969/j.issn.1671-7414.2018.04.034]
　TAN Mei-juan,LI Jing.Study on Syphilis Infection among Inpatients with Schizophrenia[J].Journal of Modern Laboratory Medicine,2018,33(03):125.[doi:10.3969/j.issn.1671-7414.2018.04.034]
[4]段侠霞a,张 燕b,贺瑞峰a,等.儿童青少年精神分裂症与血清甲状腺激素水平的相关性分析[J].现代检验医学杂志,2018,33(06):80.[doi:10.3969/j.issn.1671-7414.2018.06.021]
　DUAN Xia-xiaa,ZHANG Yanb,HE Rui-fenga,et al.Correlation Analysis on Children and Adolescents with Schizophrenia and Serum Thyroid Hormones[J].Journal of Modern Laboratory Medicine,2018,33(03):80.[doi:10.3969/j.issn.1671-7414.2018.06.021]

备注/Memo

备注/Memo:
基金项目:广东省医学科学技术研究项目(2017102391011374)。 作者简介:平军娇(1987-),女,硕士研究生,主管检验师,研究方向为精神类疾病分子生物学,E-mail:pingjunjiao@126.com。 通讯作者:杜宝国。 收稿日期:2019-03-12 修回日期:2019-02-23
更新日期/Last Update: 2019-06-20